1.
JAMA
; 328(20): 2062-2064, 2022 11 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36260754
RESUMO
This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.